Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$86.84 USD

86.84
2,837,856

+0.22 (0.25%)

Updated Aug 16, 2024 03:55 PM ET

After-Market: $86.91 +0.07 (0.08%) 7:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Pre-Markets Down on Omicron Fears

Pre-Markets Down on Omicron Fears

Moderna (MRNA) Rallies on Booster Hopes Amid Omicron Concerns

Demand for Moderna's (MRNA) COVID-19 vaccine booster dose might increase if the Omicron variant causes a rise in infection rates.

Mark Vickery headshot

Reversal on Omicron Prospects Send Markets Down

Moderna's (MRNA) Stephane Bancel told the Financial Times that the scientists he's been talking to say fighting Omicron is "not going to be good."

J&J (JNJ) to Explore Omicron Version of its COVID Vaccine

J&J (JNJ) is testing the blood serum from participants of completed and ongoing booster studies for neutralizing activity against the Omicron variant

Stock Market News for Nov 30, 2021

Benchmarks closed higher on Monday after President Joe Biden reassured Americans that despite the latest Omicron coronavirus variant scare, the country will not undergo shutdowns or lockdowns.

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax

Mark Vickery headshot

Nice Relief Rally on Biotech Assurances, Home Sales Data

The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.

Mark Vickery headshot

Nice Relief Rally on Biotech Assurances, Home Sales Data

The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.

Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?

Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.

Sanghamitra Saha headshot

ETF Areas to Gain/Lose on Fear of Omicron Strain of Coronavirus

The emergence of a new coronavirus strain, namely Omicron, has caused a massacre on Wall Street on Friday. These ETFs could gain/lose in the coming days if Omicron cases continue to rise.

Wall Street Tumbles on Resurgence of Coronavirus

Wall Street Tumbles on Resurgence of Coronavirus.

Mark Vickery headshot

Black Friday Meets "Black Friday:" New Covid Variant Hits Markets

A new Covid strain threatens the global marketplace anew, just as economic conditions around the world were beginning to get their footing following the Delta-variant fallout.

Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11

Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe

J&J (JNJ) Gets First Full Approval for COVID Jab in Canada

Canada grants full approval to J&J's (JNJ) COVID vaccine, making it the first full approval for the vaccine globally.

Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More

Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.

Sanghamitra Saha headshot

Will Thanksgiving Help Oil & Energy ETFs Despite Covid Fears?

Higher Thanksgiving demand should help oil and energy ETFs despite the renewed COVID fears.

The Zacks Analyst Blog Highlights: Alibaba, Lowe's, American Express, Boeing and Moderna

The Zacks Analyst Blog Highlights: Alibaba, Lowe's, American Express, Boeing and Moderna

Sweta Jaiswal, FRM headshot

Moderna ETFs to Rally on Positive COVID-19 Booster Shot News

Moderna is expected to gain approval for booster shots for its COVID-19 vaccine.

Mark Vickery headshot

Top Stock Reports for Alibaba, Lowe's & American Express

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Lowe's Companies, Inc. (LOW), and American Express Company (AXP).

FDA Authorizes PFE & MRNA's COVID-19 Boosters for All Adults

The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.

Stock Market News for Nov 22, 2021

Wall Street closed mixed on Friday to end a choppy week.

FDA Gives Authorization to Two COVID-19 Boosters

FDA Gives Authorization to Two COVID-19 Boosters

Mark Vickery headshot

FDA Authorizes Covid Boosters; New Fed Chair Soon?

Adults who receive booster vaccine shots will be much more highly immunized from Covid-19 than those simply "fully vaccinated."

AstraZeneca (AZN), Moderna's Heart Failure Study Successful

AstraZeneca (AZN) and Moderna are developing an mRNA-based therapeutic to treat heart failure in patients undergoing coronary artery bypass surgery.

Valneva (VALN) Stock Rises on Deal With EU for COVID-19 Jab

Valneva (VALN) enters into a supply agreement for its COVID vaccine candidate with the European Commission. The stock price surges following the news.